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Introduction: It is expected that different markers may show different patterns of association 
with different pathogenic variants within a given gene. It would be helpful to combine the 
evidence implicating association at the level of the whole gene rather than just for individual 
markers or haplotypes. Doing this is complicated by the fact that different markers do not 
represent independent sources of information.
Method: We propose combining the p values from all single locus and/or multilocus analyses 
of different markers according to the formula of Fisher, X = Σ(−2ln(pi)), and then assessing 
the empirical signiﬁ  cance of this statistic using permutation testing. We present an example 
application to 19 markers around the HTRA2 gene in a case-control study of Parkinson’s 
disease.
Results: Applying our approach shows that, although some individual tests produce low 
p values, overall association at the level of the gene is not supported.
Discussion: Approaches such as this should be more widely used in assimilating the overall 
evidence supporting involvement of a gene in a particular disease. Information can be combined 
from biallelic and multiallelic markers and from single markers along with multimarker analyses. 
Single genes can be tested or results from groups of genes involved in the same pathway could be 
combined in order to test biologically relevant hypotheses. The approach has been implemented 
in a computer program called COMBASSOC which is made available for downloading.
Keywords: Fisher, signiﬁ  cance, genetic marker
Introduction
A commonplace issue that arises when carrying out case-control studies to detect 
genetic association is that more than one marker within the same gene may support 
association. From a genetic point of view it may be expected that different markers 
may be in linkage disequilibrium (LD) with a pathogenic variant and from a biological 
point of view it may be expected that different variants within the same gene may have 
a role in inﬂ  uencing risk of disease. Often the hypothesis of interest is whether variants 
in a given gene inﬂ  uence risk rather than whether one particular marker demonstrates 
association. Hence it would be desirable to combine information from multiple 
markers in order to obtain an overall measure of the evidence implicating a gene. As 
has been discussed (Neale and Sham 2004), this issue is perhaps especially pertinent in 
the context of GWA studies. If the situation arises where a number of markers within 
a single gene achieve modest levels of signiﬁ  cance then most people would agree that 
this ﬁ  nding would be of more interest than if the same number of markers achieved 
the same results but were randomly positioned with respect to each other.
Typically, an association study claiming to ﬁ  nd evidence to support the involvement 
of a gene will present results obtained from several or many markers in the vicinity. Advances and Applications in Bioinformatics and Chemistry 2008:1 116
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A few single markers may individually produce small 
p values and results from some multimarker methods, using 
logistic regression or inferred haplotypes, may be presented 
as offering additional support. Varied numbers of markers 
in different combinations will have been studied and results 
from the analyses yielding the most positive results will be 
presented. There may be an attempt to deal with multiple 
testing issues by carrying out simulations in order to obtain 
the empirical signiﬁ  cance of the most highly signiﬁ  cant 
result. However we argue here that the main point of interest 
is not the true statistical signiﬁ  cance of only the most strongly 
positive analysis but rather the inference to be derived from 
the overall combination of results obtained from different 
markers and methods. It is this combination of results, in 
the form of p values from different single marker and multi-
marker tests, which is usually presented by the authors with 
the tacit invitation that readers use their own judgement and 
intuition to decide on the strength of the evidence implicating 
the gene in question. It would be helpful to have a formal 
method to support this process.
A number of complexities need to be dealt with. Firstly, 
markers within a gene do not represent independent sources 
of information since some will be in LD with each other. 
Also, there may be different variants inﬂ  uencing risk, perhaps 
to different extents. If this is so then alleles of some markers 
may show association through their proximity to one variant 
while other markers may detect the effect of another variant. 
Alternatively, different haplotypes of the same marker set 
may be associated with different variants. Some markers 
within the same gene may demonstrate little or no LD with 
each other and hence be relatively independent. Markers 
some distance from the coding region may nevertheless 
detect association. There may be a relatively large number of 
markers to deal with and methods which involves combining 
all into a conventional multi-marker analysis (Chapman et al 
2003, 2007; Clayton et al 2004) may be impractical, because 
of the large number of parameters involved, and/or inap-
propriate, because different variants may produce different 
patterns of association with different subsets of markers.
One early approach to tackling this issue was to consider 
combining results from groups of neighboring markers 
which were close enough to each other to be in LD (Zaykin 
et al 2002). This resulted in a series of p values produced 
from overlapping marker sets forming a sliding window 
analysis but did not produce an overall statistic at the level 
of the whole gene. A subsequent development (Chen et al 
2006) considered combining results from analysis of single 
SNPs with one overall haplotype analysis. Other approaches 
combined results from either single marker analyses 
(Hoh et al 2001; Potter 2006) or results from different 
multimarker analyses using sliding windows incorporating a 
weighting scheme for markers ﬂ  anking the central marker of 
each window (Yang et al 2006). The evaluation described in 
the ﬁ  rst of these studies (Potter 2006) showed that combining 
p values according to the method of Fisher (Fisher 1925) 
produced good power compared with other approaches. 
A method has been proposed to use extreme-value distribu-
tions to evaluate the signiﬁ  cance of results over blocks of 
markers (Dudbridge and Koeleman 2004) but it is not clear 
that this could readily be applied to the variety of different 
methods which are used to evaluate the evidence implicating 
a particular candidate gene. Here we present a natural devel-
opment of these ideas which allows the assessment of a whole 
gene. It differs from previous methods in that it uses infor-
mation from both multiple markers and multiple methods of 
analysis. Information can be combined from single marker 
analyses along with multimarker analyses using different 
numbers of markers, which may be biallelic or multallelic, 
and based on haplotypes or locus-scoring methods. No 
matter how many different methods are applied, one can 
still arrive at an overall p value which provides a measure 
of the strength of evidence supporting the hypothesesis that 
one or more variants in the gene inﬂ  uence susceptibility to 
the phenotype being studied.
Method
The approach consists of two stages. The ﬁ  rst is to combine 
the evidence for association and the second is to assess the 
strength of the evidence.
The method we use for combining p values is that due 
to Fisher (1925). This is based on the observation that, if 
n independent tests are made of the same hypothesis, then 
X = Σ(–2ln(pi)) is distributed as a χ2 with 2n df. The p values 
to be combined could be obtained from a set of single 
marker analyses or could come from both single marker and 
multimarker analyses. The summative measure obtained, 
X, could be taken to provide a combined measure of the 
strength of evidence in favor of association for a group of 
markers except that we do not expect the contributions to 
be independent.
This is dealt with by the second stage of our procedure 
which is simply to use permutation testing to assess the 
empirical signiﬁ  cance of X. If we keep the multimarker 
genotypes intact and permute case-control labels then this 
will fully deal with all the interdependencies of the markers 
due to LD between them and of interdependencies between Advances and Applications in Bioinformatics and Chemistry 2008:1 117
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the methods of analysis. Among other things it may also 
mitigate the effects of over-correcting for multiple markers 
(as could occur if a Bonferroni correction were applied), 
some of which may be scarcely informative. The procedure 
we propose for obtaining an empirical significance is 
sequential Monte Carlo testing (Besag and Clifford 1991). 
When carrying out permutation testing, rather than setting 
the number of permuted replicates, n, to a ﬁ  xed number 
one instead sets a target for r, the number of times that a 
permuted replicate should exceed the test statistic obtained 
from the real dataset. Typically the target for r might be set 
to a value of 10 or 20. One would also set some maximum 
value of n to ensure that the procedure did eventually ﬁ  n-
ish. If the target value for r is reached then the empirical 
signiﬁ  cance is given by p = r/n while if the target is not 
reached before n reaches its maximum value the empiri-
cal signiﬁ  cance is given by p = (r + 1)/(n + 1), as used in 
conventional Monte Carlo testing (North et al 2003a). The 
sequential approach produces a very valuable increase in 
speed of permutation testing when the p value to be estimated 
turns out to be non-signiﬁ  cant. If there is no association 
present then the number of permutations expected to be 
performed before the target is reached is approximated by 
r + r log((n + 1/2)/(r + 1/2)) (Besag and Clifford 1991). For 
example, with a target of r = 10 and n = 9999 then one may 
expect to perform 39.8 permutations, achieving a 250-fold 
speed increase compared with using the conventional 
method. By permuting the multimarker genotypes against 
phenotype this approach can be trusted to yield the correct 
Type 1 error rate when the null hypothesis is true.
To summarize, we propose that to obtain an overall 
measure for the strength of evidence supporting involvement 
of a gene which has been typed with a number of markers 
subjected to different single locus and multilocus methods of 
analysis one ﬁ  rst derives X = Σ(−2ln(pi)) and then assesses 
the empirical signiﬁ  cance of X using permutation testing.
In order to provide a demonstration of the approach in 
practice, we applied it to a publicly available case-control 
dataset. This consisted of consisted of 270 subjects with 
Parkinson’s disease and 271 controls genotyped for a GWA 
study using the Illumina Inﬁ  nium I and Inﬁ  nium II assays 
(Fung et al 2006) These genotypings were downloaded from 
the Coriell Institute (http://ccr.coriell.org). There has been 
a previous report that two different mutations within the 
HTRA2 gene may be associated with Parkinson’s disease 
(Strauss et al 2005). According to the UCSC browser 
(http://genome.ucsc.edu/cgi-bin/hgGateway), HTRA2 
is located on chromosome 2 at 74610040-74614191. 
We selected 19 SNPs spanning this region ranging from 
rs6718621 at 74512208 to rs10170219 at 74715172 and 
calculated individual p values testing for association with 
each marker using the SCANASSOC program (Curtis et al 
2006). In addition to single marker analyses we carried out 
haplotype-based tests for association using consecutive sets 
of two or three markers. We then applied the new approach to 
assess the overall evidence for association obtained from this 
group of 19 markers. We set a target of 10 for r, the number 
of permuted datasets to achieve the value obtained from the 
real one, and we set a maximum number of permutations, 
n, to be 9999.
Results
The results from the tests of the individual markers are shown 
in Table 1. It can be seen that one marker, rs2241027, is 
signiﬁ  cant at p = 0.04 and that two others yield p values below 
0.1. One three-marker analysis has a test-wise signiﬁ  cance 
of 0.03. We combined all 54 values according to the formula 
X = Σ(−2ln(pi)) and obtained a value of 149.4. Taking this 
as a χ2 statistic with 108 degrees of freedom would produce 
a nominal p value of 0.005. However, when we carried 
out permutation testing the target number of 10 permuted 
datasets to produce this value or higher was reached after only 
62 permutations, corresponding to an empirical signiﬁ  cance 
of 10/62 = 0.16.
Discussion
The approach we propose seems simple and to have 
face validity. It adequately deals with the issues of 
non-independence between markers and methods of analysis 
while allowing the combining of information from many 
markers from different regions of the same gene. There 
may be some beneﬁ  t in considering it in relation to other 
approaches for combining evidence from diverse sources. 
The philosophy underlying the Bonferroni correction and 
related procedures such as the estimation of the false positive 
report probability (Wacholder et al 2004) is that one is 
carrying out a number of unrelated experiments and one 
wishes to test whether for at least one of them the alternative 
hypothesis may be true. The philosophy of Fisher’s approach 
is that one is carrying out multiple independent experiments 
to test a single hypothesis. Notionally, one may then expect 
that the same effect will be present in all experiments 
although stochastic factors will impact on the results one 
obtains in practice. Thus one may expect that some studies 
may yield signiﬁ  cant results while others may, through 
chance or small sample size, be formally non-signiﬁ  cant. Advances and Applications in Bioinformatics and Chemistry 2008:1 118
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Nevertheless one will tend to see that the p values obtained 
over all experiments are smaller than would be expected 
by chance. When interpreting data from markers around a 
single gene one faces a hybrid situation. One expects that 
some markers may provide information regarding the main 
hypothesis, that the gene concerned affects the phenotype 
studied, while other markers will not be in LD with func-
tional variants and hence will behave as unrelated sources of 
essentially random effects. One way to model this situation 
would be to carry out logistic regression analysis with each 
marker being treated as an independent variable contributing 
to risk (Chapman et al 2003), although it is not clear the 
extent to which signiﬁ  cance testing based on asymptotic 
distributions would be appropriate if more than a few markers 
were included in such an analysis. Certainly, what we notice 
in practice is that authors report the best results they have 
obtained from single marker and multimarker analyses, gen-
erally without any formal attempt to consolidate the overall 
evidence implicating a gene. Our method of combining all 
results from all sources and carrying out permutation testing 
does provide a means to obtain such a summary p value.
Although we are unable to ﬁ  nd any published account, 
it appears that a somewhat similar method to ours may be 
implemented in Shaun Purcell’s PLINK program (Purcell 
et al 2007) as described in the on-line documentation 
(http://pngu.mgh.harvard.edu/∼purcell/plink/anal.shtml#set). 
According to the documentation accompanying version 0.99q 
(3 March 2007), this can carry out analyses on subsets of 
markers selected from a set designated by the user. The subset 
size is varied between a minimum and maximum size also 
speciﬁ  ed by the user and the best result obtained is deﬁ  ned in 
terms of the sum of the largest chi-squared statistics from a 
subset of each size. The overall signiﬁ  cance is then evaluated 
using a permutation procedure. We suspect that our method 
would be similar to setting both the minimum and maximum 
subset size to be equal to the size of the whole set. That is, 
one would simply sum the chi-squared results for all markers. 
However the documentation implies that one should avoid 
doing this by setting the maximum subset size to a “reason-
able number” in order to avoid performing an “unnecessary 
number of tests”. If the minimum and maximum sizes differ 
then in fact additional tests are performed for the different 
sizes. Our approach explicitly addresses the possibility that 
different kinds of analysis might be used. The software 
we have implemented allows incorporation of locus-based 
logistic regression as well as haplotype-based analyses. 
In principle other methods of analysis, for example neural 
network analysis (North et al 2003b) or haplotype clustering 
methods (Knight et al 2008), could be accommodated. Our 
approach deﬁ  nes in advance the markers of interest and 
Table 1 Markers spanning HTRA2 showing individual p values obtained for tests for association with Parkinson’s disease
Marker Position P value
     Single marker Two markers Three markers
rs6718621 74512208 0.104 0.223 0.343
rs6751601 74536436 0.224 0.084 0.501
rs2240444 74553279 0.061 0.225 0.357
rs2268424 74560023 0.133 0.303 0.596
rs2268420 74566516 0.689 0.564 0.728
rs2268418 74576122 0.166 0.505 0.623
rs7556852 74581170 0.200 0.392 0.691
rs6746854 74593157 0.218 0.326 0.326
rs1063588 74602033 0.149 0.149 0.259
rs1047911 74611433 0.149 0.259 0.136
rs6707475 74622146 0.206 0.109 0.141
rs2301984 74632710 0.155 0.218 0.404
rs2240442 74645428 0.097 0.255 0.260
rs3806607 74647269 0.212 0.152 0.034
rs2241027 74670321 0.041 0.175 0.369
rs6707302 74673077 0.273 0.637 0.617
rs7562200 74688601 0.841 0.326 0.515
rs11126435 74701355 0.126 0.465
rs10170219 74715172 1.000Advances and Applications in Bioinformatics and Chemistry 2008:1 119
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takes a summary statistic derived from all their p values 
simultaneously. Likewise, previous work suggests that, at 
least in some situations, more powerful tests will result if only 
p values below a certain threshold are combined (Zaykin et al 
2002). Once again, the choice of threshold is arbitrary and it 
is not clear that using this truncation will always be of beneﬁ  t. 
The exploration of the advantages and disadvantages of each 
approach could be the subject of further investigation.
Our example application does not provide support for 
association between Parkinson’s disease and HTRA2. 
Different conclusions might have been drawn had there 
been a stronger prior hypothesis, for example if the three 
markers with p   0.1 had been speciﬁ  cally implicated in other 
studies. At the level of the gene, however, our overall result is 
negative. There appear to be more small p values than would 
be expected by chance (as is clear from the Σ(–2ln(pi))) so a 
naïve interpretation might have been that these markers did 
support association. However once we apply our permutation 
we can see that, because of the non-independence of the 
p values, in fact the results are well within chance expectation. 
This demonstrates the value of our approach in being able to 
summarize the available evidence.
A number of extensions to this basic approach could be 
developed. We should begin by pointing out that even as it 
stands the method can combine information from biallelic 
and multiallelic markers. It can also combine information 
from both single marker analyses and multimarker analyses. 
Thus one might wish to treat some sets of markers as being 
suitable for haplotype analysis and combine the information 
from these with results from other markers or groups of 
markers. As demonstrated in the example above, one can 
also combine results from single marker and multimarker 
analysis of the same markers. That is, if one had 4 markers 
one could combine the 4 single marker p values along with 
a p value obtained from haplotype analysis of all of them. 
Using multiple methods of analysis may risk reducing 
power somewhat but the overall signiﬁ  cance level obtained 
remains valid.
Other ways could be considered to combine the individual 
p values. For example, more weight could be given to markers 
within coding regions or those closer to rather than further 
from the gene or those having been implicated in previous 
studies. Again, the permutation testing will ensure that 
whatever method is used to combine them the empirical 
signiﬁ  cance level will still be valid. Results from functionally 
related groups of genes could be combined. This would 
provide evidence to implicate a particular pathway or system 
rather than an individual gene.
We should note some situations in which the empirical 
signiﬁ  cance level would not be valid. The main principle 
is that the p values to be combined must not be selected on 
a post hoc basis. For example, one must not notice that a 
particular intron contains a number of interesting results and 
then combine the results just from that intron. One cannot 
elect to include markers from some distance away after 
seeing that some appear to support association. One cannot 
perform a number of different multimarker analyses and then 
include the results from only the most signiﬁ  cant ones. One 
can apply this approach to a gene which appears interesting 
based on the fact that a number of markers within it appear 
to show some evidence for association but only if one then 
proceeds to make a standard multiple-testing correction for 
all the other genes for which genotypes were obtained.
We acknowledge that although our approach may 
appear theoretically attractive we are not currently able to 
present clear evidence regarding its power compared with 
other methods. This is because it is intended to deal with 
a situation which is biologically plausible – that different 
mutations in the same gene might each have an effect on 
a given phenotype – but for which real data are lacking 
and for which plausible computer simulations would be 
technically difﬁ  cult. One would need to model datasets in 
which multiple mutations occurred within the same gene 
along with the complex and realistic LD relationships for 
markers around each mutation. We have previously studied 
such models in the context of a single mutation (North et al 
2006) but have not as yet produced a procedure to carry 
out systematic studies of the simulated effects of multiple 
mutations. We do not expect that the approach would be 
any more powerful than pre-existing methods in the simple 
situation of a single mutation. Although we cannot claim 
to have demonstrated that the approach is necessarily more 
powerful than other methods, we are conﬁ  dent at least that the 
permutation procedure means that the overall result is valid, 
that is that the Type 1 error rate is correct. This means that 
our approach does at least provide a way of summarizing 
the available evidence implicating a particular region rather 
than having to rely upon the reader’s subjective judgment 
based on a number of non-independent p values obtained 
from different analyses.
The method for combining results from different analyses 
has been implemented in the COMBASSOC program, 
which is available along with the other programs to support 
GENECOUNTING (Zhao et al 2002), available from our 
website at: www.mds.qmul.ac.uk/statgen. Analyses can 
consist of any number of single marker tests, multimarker Advances and Applications in Bioinformatics and Chemistry 2008:1 120
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haplotype analyses and multimarker locus-wise analyses 
using logistic regression. If desired, different subsets of 
markers can be selected for different analyses. No matter 
how many different tests are performed, results from all are 
combined to produce one overall measure of the strength 
of evidence in favor of association and the empirical 
signiﬁ  cance of this is derived using permutation testing, 
providing a single overall p value.
We hope that the approach outlined will prove attractive 
and practical. It provides a simple and intuitive way to 
provide some objective assessment of the overall evidence 
for association produced by a group of markers. We consider 
such an approach to be preferred to the widespread practice 
of quoting the individual signiﬁ  cance of a number of different 
single marker and/or multimarker analyses and leaving 
it to the reader to form some kind of judgement as to the 
implication of the results.
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